Physician profile
Eric D High
NPI 1730184284
$10,858.71
in general payments reported to CMS, 2019-2025
41 companies · $3,735 in 2025
The $3,735 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $856 · 2021: $1,445 · 2022: $818 · 2023: $1,107 · 2024: $1,763 · 2025: $3,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,578 · Consulting Fee: $600 · Travel and Lodging: $400 · Education: $26.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,578.10 |
| Consulting Fee | $600.00 |
| Travel and Lodging | $400.00 |
| Education | $26.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,372.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,142.97 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,043.26 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Olympus Medical Systems Corporation | $1,000.00 | 2025 | Gastrointestinal Videoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $692.00 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $598.54 | 2022-2025 | Ibsrela |
| Romark Laboratories, Lc | $480.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $368.60 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $310.76 | 2019-2024 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $290.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $239.63 | 2019-2025 | |
| Lilly USA, LLC | $219.28 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $214.78 | 2020-2023 | Dificid |
| Genzyme Corporation | $182.15 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $177.60 | 2020-2025 | Ocaliva |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $146.31 | 2020-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $135.57 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $121.06 | 2019-2025 | Livdelzi |
| Ironwood Pharmaceuticals, INC | $99.41 | 2019-2023 | Linzess |
| Celgene Corporation | $99.04 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $87.71 | 2024-2025 | Vegzelma |
| Csl Behring | $80.60 | 2021-2023 | Kcentra |
| Redhill Biopharma INC. | $75.83 | 2020-2021 | |
| Organon LLC | $75.03 | 2023-2025 | Hadlima, Renflexis |
| Amgen INC. | $67.42 | 2020-2023 | Amjevita, Avsola |
| Novo Nordisk INC | $66.09 | 2020-2025 | Wegovy |
| Aimmune Therapeutics, INC. | $53.43 | 2024-2025 | Zenpep |
| Shire North American Group INC | $52.64 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $47.68 | 2025 | Iqirvo |
| Allergan, INC. | $47.21 | 2019 | |
| Amag Pharmaceuticals, INC. | $46.56 | 2019 | |
| Blue Earth Diagnostics | $44.32 | 2022 | |
| Alfasigma USA, INC. | $42.58 | 2020 | |
| Tempus Ai, INC | $21.14 | 2024 | |
| Vivus LLC | $20.65 | 2025 | Pancreaze |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Fresenius Kabi USA, LLC | $16.05 | 2023 | Idacio |
| Endo Pharmaceuticals INC. | $15.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.64 | 2022 | |
| Ucb, INC. | $13.95 | 2019 | |
| Evoke Pharma, INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.